A 2025 52-week randomized trial in adults with heterozygous familial hypercholesterolemia (HeFH) found that daily oral Enlicitide 20 mg reduced low-density lipoprotein (LDL) cholesterol by an average of 58% at 24 weeks and maintained about a 55% reduction at 52 weeks versus placebo.
November 21, 2025
high
temporal
Global randomized clinical trial of Enlicitide in adults with genetically elevated LDL cholesterol already on lipid-lowering therapy.
A 2025 trial of Enlicitide reported additional lipid improvements: non-high-density lipoprotein (non-HDL) cholesterol decreased by 52%, apolipoprotein B decreased by 48%, and lipoprotein(a) decreased by nearly 25% in the treatment group.
November 21, 2025
high
temporal
Secondary lipid endpoint changes observed in the same 52-week Enlicitide clinical trial.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapies are typically administered by injection every few weeks, while Enlicitide was administered orally as a once-daily 20 mg pill in the 2025 trial.
November 21, 2025
high
comparative
Modes of administration for lipid-lowering therapies compared to the oral dosing regimen used for Enlicitide in the trial.